Article
Pharmacology & Pharmacy
Yu Mei, Xijia Feng, Tienan Feng, Min Yan, Zhenggang Zhu, Tian Li, Zhenglun Zhu
Summary: This retrospective study examined the role of adjuvant chemotherapy (ACT) in patients with pT2N0M0 gastric cancer who underwent radical resection. The study found that ACT was associated with higher 5-year overall survival and disease-specific survival rates. Patients with pT2N0M0 gastric cancer, regardless of high-risk factors, may be suitable for ACT.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Jennifer R. Bellon, Nabihah Tayob, David D. Yang, Jordan Tralins, Chau T. Dang, Steven J. Isakoff, Michelle DeMeo, Harold J. Burstein, Ann H. Partridge, Eric P. Winer, Ian E. Krop, Sara M. Tolaney
Summary: This study evaluated the safety and efficacy of radiation therapy among HER2-positive breast cancer patients receiving adjuvant trastuzumab emtansine or paclitaxel plus trastuzumab. The results showed that radiation therapy was well-tolerated when given concurrently with either T-DM1 or TH, and hypofractionation resulted in lower grade >= 2 acute skin toxicity in BCS patients.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Review
Medicine, General & Internal
Toshizo Takayama, Yasushi Tsuji
Summary: Surgical resection is the best curative option for gastric cancer, but patients with advanced disease have poor prognosis even after surgery. To reduce the risk of recurrence, perioperative chemotherapy has been combined with surgery, and different standard chemotherapy regimens have been developed in East Asia, Europe, and North America. In recent years, the use of novel agents such as molecular-targeted drugs and immune checkpoint inhibitors in perioperative therapy has shown promising results in these regions.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Wenjie Ni, Shufei Yu, Zefen Xiao, Zongmei Zhou, Dongfu Chen, Qinfu Feng, Jun Liang, Jima Lv, Shugeng Gao, Yousheng Mao, Qi Xue, Kelin Sun, Xiangyang Liu, Dekang Fang, Jian Li, Dali Wang, Jun Zhao, Yushun Gao
Summary: The study demonstrated that postoperative radiotherapy/postoperative concurrent chemoradiotherapy (PORT/POCRT) could significantly improve disease-free survival and overall survival in patients with stage IIB-III esophageal squamous cell carcinoma.
Article
Oncology
Caressa Hui, Agnes Ewongwo, Brianna Lau, George Fisher, Daniel Delitto, George Poultsides, Quoc-Anh Ho, Elham Rahimy, Erqi Pollom, Daniel T. Chang, Lucas K. Vitzthum
Summary: Improved treatment strategies are needed for patients with locally advanced gastric cancer with poor response to neoadjuvant chemotherapy. This study aimed to describe patterns of failure for patients with no or partial response (NR, PR) to preoperative chemotherapy.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Jiao-Bao Huang, Jun Lu, Dong Wu, Bin-bin Xu, Zhen Xue, Guo-Sheng Lin, Hua-Long Zheng, Li-Li Shen, Jia Lin, Jian-Wei Xie, Jia-Bin Wang, Jian-Xian Lin, Qi-Yue Chen, Long-Long Cao, Chao-Hui Zheng, Chang-Ming Huang, Ping Li
Summary: For patients with pT3N0M0 gastric cancer, at least three cycles of postoperative adjuvant chemotherapy can significantly reduce the overall recurrence rate.
FRONTIERS IN ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Guojun Chen, Zhitong Chen, Zejun Wang, Richard Obenchain, Di Wen, Hongjun Li, Richard E. Wirz, Zhen Gu
Summary: The cold atmospheric plasma (CAP) post-surgical treatment effectively induces immunogenic cell death in residual tumor cells and evokes T cell-mediated immune responses to combat them, contributing to tumor growth inhibition and prolonged survival in cancer models.
Article
Medicine, General & Internal
Eric Anderson, Alexis LeVee, Sungjin Kim, Katelyn Atkins, Michelle Guan, Veronica Placencio-Hickok, Natalie Moshayedi, Andrew Hendifar, Arsen Osipov, Alexandra Gangi, Miguel Burch, Kevin Waters, May Cho, Samuel Klempner, Joseph Chao, Mitchell Kamrava, Jun Gong
Summary: The study reveals that neoadjuvant chemoradiation (nCRT) is associated with the highest rate of pathologic complete response, while neoadjuvant and adjuvant chemotherapy (CTTU) is associated with the best overall survival.
Article
Oncology
Alexandra Diggs, Tiffany Y. Sia, Yongmei Huang, Allison Gockley, Alexander Melamed, Fady Khoury-Collado, Caryn St. Clair, June Y. Hou, Dawn L. Hershman, Jason D. Wright
Summary: This study analyzed the utilization of adjuvant chemotherapy and radiation therapy in patients with stage II and III uterine leiomyosarcoma (uLMS). The results showed that the use of chemotherapy is increasing while the use of radiation therapy is decreasing. Radiation therapy is associated with improved survival in both stage II and III disease, but there is no association between adjuvant chemotherapy and survival in stage II patients.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Yaobin Lin, Lei Wang, Lingdong Shao, Xueqing Zhang, Huaqin Lin, Youjia Wang, Junxin Wu
Summary: A study on the clinical efficacy of adjuvant external beam radiotherapy for patients with pathologic stage T4b sigmoid colon cancer found that patients who received adjuvant EBRT had a significantly longer median overall survival compared to those who did not receive radiation therapy. Age, serum carcinoembryonic antigen (CEA) level, perineural invasion, lymph node dissection (LND) number, and adjuvant EBRT were identified as independent factors associated with overall survival. A risk-stratification model was developed to predict the outcomes of high-risk patients based on specific factors.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
S. Senan, M. Ozguroglu, D. Daniel, A. Villegas, D. Vicente, S. Murakami, R. Hui, C. Faivre-Finn, L. Paz-Ares, Y. L. Wu, H. Mann, P. A. Dennis, S. J. Antonia
Summary: Durvalumab improves progression-free survival and overall survival in patients with or without stage IIIA-N2 non-small-cell lung cancer (NSCLC). Further research is needed to determine the optimal treatment approach for patients who are deemed operable.
Article
Medicine, General & Internal
Jian-Xian Lin, Yi-Hui Tang, Guan-Jie Lin, Yu-Bin Ma, Jacopo Desiderio, Ping Li, Jian-Wei Xie, Jia-Bin Wang, Jun Lu, Qi-Yue Chen, Long-Long Cao, Mi Lin, Ru-Hong Tu, Chao-Hui Zheng, Amilcare Parisi, Mark J. Truty, Chang-Ming Huang
Summary: This cohort study compares the survival rates of patients with locally advanced gastric cancer who received adjuvant chemotherapy (AC) and those who did not after neoadjuvant chemotherapy followed by surgery. The study found that AC was associated with improved survival in patients with a lymph node ratio of at least 9%. These findings suggest that the lymph node ratio could be useful in AC selection for locally advanced gastric cancer in future decision-making processes.
Article
Oncology
Takefumi Komiya, Shinkichi Takamori, Gregory Wilding
Summary: This study suggests that adjuvant radiation may still play a role in improving overall survival in patients with persistent N2 disease after neoadjuvant chemotherapy. Adjuvant radiation may have a beneficial effect in patients who are not downstaged to pN0-1.
RADIOTHERAPY AND ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Chihiro Sato, Hisato Kawakami, Ryo Tanaka, Hironaga Satake, Kentaro Inoue, Yutaka Kimura, Junya Fujita, Ryohei Kawabata, Yasutaka Chiba, Taroh Satoh, Kazuhiko Nakagawa
Summary: Adjuvant S-1 monotherapy is the standard treatment for stage II gastric cancer after curative resection in Japan. The efficacy of S-1 for microsatellite instability-high (MSI-H) tumors remained unknown. This study found that MSI-H stage II gastric cancer patients had better adjusted survival than microsatellite-stable (MSS) patients treated with S-1 adjuvant therapy. The mechanisms of recurrence differed between MSI-H and MSS tumors.
SCIENTIFIC REPORTS
(2023)
Review
Oncology
Caroline Fong, Edwina Johnston, Naureen Starling
Summary: Gastric cancer requires a multimodality approach to achieve optimal curative rates. Preferences for neoadjuvant and adjuvant approaches vary across the globe, but a multimodal approach provides clear survival benefits compared to surgery alone. However, the completion rates of adjuvant therapy are low, highlighting the need for patient selection optimization and individualized treatment strategies.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2022)
Article
Oncology
Taroh Satoh, Yoon-Koo Kang, Yee Chao, Min-Hee Ryu, Ken Kato, Hyun Cheol Chung, Jen-Shi Chen, Kei Muro, Won Ki Kang, Kun-Huei Yeh, Takaki Yoshikawa, Sang Cheul Oh, Li-Yuan Bai, Takao Tamura, Keun-Wook Lee, Yasuo Hamamoto, Jong Gwang Kim, Keisho Chin, Do-Youn Oh, Keiko Minashi, Jae Yong Cho, Masahiro Tsuda, Mitsunobu Tanimoto, Li-Tzong Chen, Narikazu Boku
Article
Surgery
Yukinori Kurokawa, Hiroya Takeuchi, Yuichiro Doki, Shinji Mine, Masanori Terashima, Takushi Yasuda, Kazuhiro Yoshida, Hiroyuki Daiko, Shinichi Sakuramoto, Takaki Yoshikawa, Chikara Kunisaki, Yasuyuki Seto, Shigeyuki Tamura, Toshio Shimokawa, Takeshi Sano, Yuko Kitagawa
Summary: This study accurately identified the distribution of lymph node metastases from EGJ tumors and determined the optimal extent of subsequent lymph node dissection.
Article
Oncology
Kohei Shitara, Hiroki Hara, Takaki Yoshikawa, Kazumasa Fujitani, Tomohiro Nishina, Ayumu Hosokawa, Takashi Asakawa, Satoe Kawakami, Kei Muro
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2020)
Article
Oncology
Yoshiaki Iwasaki, Masanori Terashima, Junki Mizusawa, Hiroshi Katayama, Kenichi Nakamura, Hitoshi Katai, Takaki Yoshikawa, Seiji Ito, Masahide Kaji, Yutaka Kimura, Motohiro Hirao, Makoto Yamada, Akira Kurita, Masakazu Takagi, Sang-Woong Lee, Akinori Takagane, Hiroshi Yabusaki, Jun Hihara, Narikazu Boku, Takeshi Sano, Mitsuru Sasako
Summary: For scirrhous-type gastric cancer, neoadjuvant chemotherapy with S-1 plus cisplatin did not demonstrate a survival benefit, with D2 surgery followed by adjuvant chemotherapy remaining the standard treatment.
Meeting Abstract
Oncology
Hitoshi Katai, Yuichiro Doki, Yukinori Kurokawa, Junki Mizusawa, Takaki Yoshikawa, Yutaka Kimura, Shuji Takiguchi, Yasunori Nishida, Takeshi Sano, Kenichi Nakamura, Mitsuru Sasako, Masanori Terashima
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Meeting Abstract
Oncology
Takanobu Yamada, Takaki Yoshikawa, Junki Mizusawa, Hitoshi Katai, Akinori Takagane, Shinji Okano, Shin Teshima, Hisayuki Matsushita, Masahiro Goto, Jun Hihara, Yoshiyuki Kawashima, Takeshi Omori, Hisashi Shinohara, Yasuhiro Yuasa, Hiroshi Katayama, Haruhiko Fukuda, Narikazu Boku, Masanori Terashima, Takeshi Sano, Mitsuru Sasako
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Meeting Abstract
Oncology
Rie Makuuchi, Mitsumi Terada, Junki Mizusawa, Masanori Tokunaga, Kei Hosoda, Toshiyasu Ojima, Takeshi Omori, Kazuhisa Ehara, Masaya Watanabe, Akinori Takagane, Yasunori Nishida, Yoshitomo Yanagimoto, Narikazu Boku, Takaki Yoshikawa, Masanori Terashima
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Meeting Abstract
Oncology
Shuichi Hironaka, Ryo Sadachi, Tadayoshi Hashimoto, Nozomu Machida, Satoru Iwasa, Yasuhide Yamada, Mitsuru Sasako, Narikazu Boku, Takaki Yoshikawa, Masanori Terashima
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Yuichi Ito, Kazumasa Fujitani, Kentaro Sakamaki, Masahiko Ando, Ryohei Kawabata, Yutaka Tanizawa, Takaki Yoshikawa, Takanobu Yamada, Motohiro Hirao, Makoto Yamada, Jun Hihara, Ryoji Fukushima, Yasuhiro Choda, Yasuhiro Kodera, Shin Teshima, Hisashi Shinohara, Masato Kondo
Summary: Palliative surgery improved solid food intake but did not improve quality of life in patients with peritoneal dissemination of gastric cancer. The rate of postoperative complications and mortality was acceptable.
Article
Oncology
Narikazu Boku, Taroh Satoh, Min-Hee Ryu, Yee Chao, Ken Kato, Hyun Cheol Chung, Jen-Shi Chen, Kei Muro, Won Ki Kang, Kun-Huei Yeh, Takaki Yoshikawa, Sang Cheul Oh, Li-Yuan Bai, Takao Tamura, Keun-Wook Lee, Yasuo Hamamoto, Jong Gwang Kim, Keisho Chin, Do-Youn Oh, Keiko Minashi, Jae Yong Cho, Masahiro Tsuda, Taihei Nishiyama, Li-Tzong Chen, Yoon-Koo Kang
Summary: The study confirmed the long-term efficacy of nivolumab in patients with advanced gastric cancer, showing a longer overall survival compared to placebo. Nivolumab also demonstrated potential benefits in the treatment beyond disease progression.
Article
Oncology
Yoon-Koo Kang, Satoshi Morita, Taroh Satoh, Min-Hee Ryu, Yee Chao, Ken Kato, Hyun Cheol Chung, Jen-Shi Chen, Kei Muro, Won Ki Kang, Kun-Huei Yeh, Takaki Yoshikawa, Sang Cheul Oh, Li-Yuan Bai, Takao Tamura, Keun-Wook Lee, Yasuo Hamamoto, Jong Gwang Kim, Keisho Chin, Do-Youn Oh, Keiko Minashi, Jae Yong Cho, Masahiro Tsuda, Hiroki Sameshima, Li-Tzong Chen, Narikazu Boku
Summary: The study identified a combination of age, peritoneal metastasis, and serum sodium level as potential predictors of benefit from nivolumab salvage therapy in advanced gastric or gastroesophageal junction cancer patients, especially for those with higher risk factors.
Review
Oncology
Akira Tsuburaya, Jia Guan, Kazuhiro Yoshida, Michiya Kobayashi, Shigefumi Yoshino, Kazuaki Tanabe, Takaki Yoshikawa, Takashi Oshima, Yumi Miyashita, Junichi Sakamoto, Shiro Tanaka
Summary: The study identified age as a significant prognostic factor in both surgery alone and adjuvant group. Adjuvant therapy was effective for every TN stage, with a tendency to be more effective in T1-2 tumors. CAPOX was found to be more effective for differentiated T1-2 tumors with lymph node metastasis.
Article
Oncology
Takaomi Hagi, Yukinori Kurokawa, Junki Mizusawa, Takeo Fukagawa, Hitoshi Katai, Takeshi Sano, Kazunari Misawa, Norimasa Fukushima, Yasuyuki Kawachi, Mitsuru Sasako, Takaki Yoshikawa, Masanori Terashima
Summary: In this study, the authors evaluated the tumor-related factors that might affect the diagnostic accuracy of preoperative T staging in gastric cancer. They found that tumor location, macroscopic type, and histological type could have an impact on the accuracy of the diagnosis.
Article
Oncology
Toru Aoyama, Takaki Yoshikawa, Satoshi Ida, Haruhiko Cho, Kentaro Sakamaki, Yuichi Ito, Kazumasa Fujitani, Nobuhiro Takiguchi, Yoshiyuki Kawashima, Kazuhiro Nishikawa, Soya Nunobe, Naoki Hiki
Summary: This study investigated the effect of perioperative eicosapentaenoic acid (EPA) on the survival of patients with localized gastric cancer. The results showed that EPA did not significantly improve the survival rate of patients. Further research should be conducted in patients with unfavorable advanced gastric cancer.
Article
Gastroenterology & Hepatology
Masanori Terashima, Kazumasa Fujitani, Han-Kwang Yang, Junki Mizusawa, Toshimasa Tsujinaka, Kenichi Nakamura, Hiroshi Katayama, Hyuk-Joon Lee, Jun Ho Lee, Ji-Yeong An, Akinori Takagane, Young-Kyu Park, Seung Ho Choi, Kyo Young Song, Seiji Ito, Do Joong Park, Sung-Ho Jin, Narikazu Boku, Takaki Yoshikawa, Mitsuru Sasako
Summary: The REGATTA trial showed no survival benefit from reduction gastrectomy in advanced gastric cancer patients with a single non-curable factor. However, the treatment effect varied based on tumor location and country. Further analysis revealed worse overall survival in gastrectomy plus chemotherapy arm in Japan, but not in Korea.
ANNALS OF GASTROENTEROLOGICAL SURGERY
(2023)
